Grace Therapeutics (GRCE) Competitors $3.39 +0.05 (+1.50%) As of 09:30 AM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock GRCE vs. NMRA, NVCT, DERM, BIOA, IMAB, IPHA, CRBU, SPRO, DMAC, and IMRXShould you be buying Grace Therapeutics stock or one of its competitors? The main competitors of Grace Therapeutics include Neumora Therapeutics (NMRA), Nuvectis Pharma (NVCT), Journey Medical (DERM), BioAge Labs (BIOA), I-Mab (IMAB), Innate Pharma (IPHA), Caribou Biosciences (CRBU), Spero Therapeutics (SPRO), DiaMedica Therapeutics (DMAC), and Immuneering (IMRX). These companies are all part of the "pharmaceutical products" industry. Grace Therapeutics vs. Its Competitors Neumora Therapeutics Nuvectis Pharma Journey Medical BioAge Labs I-Mab Innate Pharma Caribou Biosciences Spero Therapeutics DiaMedica Therapeutics Immuneering Grace Therapeutics (NASDAQ:GRCE) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability. Do insiders and institutionals hold more shares of GRCE or NMRA? 6.1% of Grace Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 13.5% of Grace Therapeutics shares are held by company insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, GRCE or NMRA? Grace Therapeutics has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.75, meaning that its share price is 175% more volatile than the S&P 500. Is GRCE or NMRA more profitable? Grace Therapeutics' return on equity of -19.45% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Grace TherapeuticsN/A -19.45% -16.99% Neumora Therapeutics N/A -84.79%-77.57% Does the media refer more to GRCE or NMRA? In the previous week, Neumora Therapeutics had 3 more articles in the media than Grace Therapeutics. MarketBeat recorded 4 mentions for Neumora Therapeutics and 1 mentions for Grace Therapeutics. Grace Therapeutics' average media sentiment score of 1.91 beat Neumora Therapeutics' score of 0.80 indicating that Grace Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Grace Therapeutics Very Positive Neumora Therapeutics Positive Which has higher valuation and earnings, GRCE or NMRA? Grace Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGrace TherapeuticsN/AN/A-$9.57M-$0.89-3.81Neumora TherapeuticsN/AN/A-$243.79M-$1.61-0.95 Do analysts rate GRCE or NMRA? Grace Therapeutics presently has a consensus price target of $12.00, indicating a potential upside of 253.98%. Neumora Therapeutics has a consensus price target of $7.14, indicating a potential upside of 368.38%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Grace Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Grace Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 SummaryNeumora Therapeutics beats Grace Therapeutics on 7 of the 13 factors compared between the two stocks. Get Grace Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRCE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRCE vs. The Competition Export to ExcelMetricGrace TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$46.88M$2.91B$5.51B$9.31BDividend YieldN/A2.46%4.25%4.09%P/E Ratio-3.8120.3628.1819.72Price / SalesN/A290.30439.19110.06Price / CashN/A42.3835.5357.53Price / Book0.707.768.235.67Net Income-$9.57M-$55.11M$3.23B$257.51M7 Day Performance9.35%0.19%-0.61%-0.16%1 Month Performance18.53%10.80%6.63%9.89%1 Year PerformanceN/A-0.68%27.07%15.08% Grace Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRCEGrace Therapeutics2.549 of 5 stars$3.39+1.5%$12.00+254.0%N/A$46.88MN/A-3.81N/APositive NewsGap UpNMRANeumora Therapeutics2.705 of 5 stars$1.06+3.9%$7.50+607.5%-88.2%$171.45MN/A-0.66108News CoverageAnalyst ForecastGap UpNVCTNuvectis Pharma3.3264 of 5 stars$8.19+1.4%$17.00+107.6%+18.4%$171.09MN/A-7.258DERMJourney Medical2.4206 of 5 stars$7.22+1.1%$9.50+31.6%+21.8%$168.23M$56.13M-18.5190BIOABioAge LabsN/A$4.68+1.1%N/AN/A$167.78MN/A0.00N/AIMABI-Mab2.8522 of 5 stars$2.05-11.3%$6.00+192.7%+31.9%$167.40MN/A0.00380Gap DownIPHAInnate Pharma2.8094 of 5 stars$1.81+5.2%$11.00+507.7%-16.3%$166.84M$12.62M0.00220News CoverageCRBUCaribou Biosciences2.9145 of 5 stars$1.74-0.6%$8.50+388.5%-33.0%$161.82M$9.99M-1.07100Positive NewsGap UpSPROSpero Therapeutics3.9283 of 5 stars$2.84-6.6%$5.00+76.1%+64.7%$158.78M$47.98M-2.22150DMACDiaMedica Therapeutics1.1753 of 5 stars$3.67-4.7%$8.00+118.0%+17.4%$157.38MN/A-5.7320IMRXImmuneering3.3765 of 5 stars$4.33-2.7%$13.25+206.0%+216.8%$155.84M$320K-2.2160Positive News Related Companies and Tools Related Companies Neumora Therapeutics Alternatives Nuvectis Pharma Alternatives Journey Medical Alternatives BioAge Labs Alternatives I-Mab Alternatives Innate Pharma Alternatives Caribou Biosciences Alternatives Spero Therapeutics Alternatives DiaMedica Therapeutics Alternatives Immuneering Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRCE) was last updated on 7/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GRCE Stock Alerts